Investment Thesis
Despite impressive 27.8% YoY revenue growth, Oncology Institute exhibits severe financial distress with negative stockholders equity (-$15.7M), persistent operating losses (-$36.1M), and negative operating cash flow (-$24.6M), indicating the company cannot sustain operations profitably. The deteriorating net income (-20.5% YoY), inability to service debt (interest coverage of -267.3x), and ongoing cash burn of $27.8M in free cash flow threaten long-term viability despite $33.6M in remaining cash.
Strengths
- Strong top-line revenue growth of 27.8% YoY ($502.7M)
- Adequate short-term liquidity with 1.59x current ratio and $33.6M cash balance
- Operating in growing healthcare services sector with demographic tailwinds
Risks
- Technical insolvency with negative stockholders equity of -$15.7M (liabilities exceed assets)
- Negative operating cash flow (-$24.6M) and free cash flow (-$27.8M) indicating unsustainable operations
- Inability to service debt with interest coverage ratio of -267.3x and $77.4M long-term debt burden
- Deteriorating profitability with net losses of -$60.6M and worsening net margin of -12.1%
- Revenue growth not translating to profitability (EPS worsened despite revenue expansion)
- Limited cash runway at current burn rate; likely requires capital raise or restructuring
Key Metrics to Watch
- Quarterly trend in operating cash flow toward positive territory
- Path to EBITDA and operating income breakeven
- Debt restructuring announcements or covenant violations
- Cash balance and estimated runway months
- Gross margin expansion and cost structure improvements
Financial Metrics
Revenue
502.7M
Net Income
-60.6M
EPS (Diluted)
$-0.54
Free Cash Flow
-27.8M
Total Assets
164.7M
Cash
33.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-7.2%
Net Margin
-12.1%
ROE
N/A
ROA
-36.8%
FCF Margin
-5.5%
Balance Sheet & Liquidity
Current Ratio
1.59x
Quick Ratio
1.35x
Debt/Equity
N/A
Debt/Assets
109.5%
Interest Coverage
-267.28x
Long-term Debt
77.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T16:24:21.344424 |
Data as of: 2025-12-31 |
Powered by Claude AI